Lukas C. Amler

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index53

i10-index80

Publications295

Citations13,899

Grants

No NSF/NIH grants on record.

0.0005

PageRank within Pulmonary and Respiratory Medicine co-authorship network

New preprint: Supplementary Figures 1 - 9 from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit2023-03-31
New paper: Supplementary Tables 1 - 7 from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit2023-03-31

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Last latest available · showing 8 of 8